PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Australian Clinical Labs Limited (ACL.AX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

AU0000148496

Sector

Healthcare

Highlights

Market Cap

A$718.06M

EPS (TTM)

A$0.12

PE Ratio

29.83

Total Revenue (TTM)

A$359.10M

Gross Profit (TTM)

A$136.09M

EBITDA (TTM)

A$45.83M

Year Range

A$2.08 - A$3.86

Target Price

A$3.80

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of A$10,000 in Australian Clinical Labs Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%20.00%40.00%60.00%AugustSeptemberOctoberNovemberDecember2025
50.12%
12.26%
ACL.AX (Australian Clinical Labs Limited)
Benchmark (^GSPC)

Returns By Period

Australian Clinical Labs Limited had a return of 0.58% year-to-date (YTD) and 19.92% in the last 12 months.


ACL.AX

YTD

0.58%

1M

-0.00%

6M

45.22%

1Y

19.92%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.77%

1M

-3.55%

6M

3.64%

1Y

22.00%

5Y*

12.20%

10Y*

11.23%

*Annualized

Monthly Returns

The table below presents the monthly returns of ACL.AX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20243.81%-20.33%13.81%-9.67%-5.76%9.60%1.20%18.11%25.80%-1.09%-4.41%-0.86%23.76%
20234.03%16.45%-0.29%0.00%-9.91%8.18%-7.85%-6.94%-1.04%-5.61%-2.60%10.31%1.29%
2022-17.90%-8.25%12.46%0.39%0.39%-11.22%15.25%-8.54%-20.14%-4.25%0.30%-12.09%-46.13%
20214.39%-4.76%14.12%15.72%0.67%-3.10%-2.97%45.88%81.29%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACL.AX is 66, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ACL.AX is 6666
Overall Rank
The Sharpe Ratio Rank of ACL.AX is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of ACL.AX is 6464
Sortino Ratio Rank
The Omega Ratio Rank of ACL.AX is 6363
Omega Ratio Rank
The Calmar Ratio Rank of ACL.AX is 6666
Calmar Ratio Rank
The Martin Ratio Rank of ACL.AX is 6565
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Australian Clinical Labs Limited (ACL.AX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ACL.AX, currently valued at 0.64, compared to the broader market-2.000.002.000.641.73
The chart of Sortino ratio for ACL.AX, currently valued at 1.07, compared to the broader market-4.00-2.000.002.004.001.072.33
The chart of Omega ratio for ACL.AX, currently valued at 1.14, compared to the broader market0.501.001.502.001.141.32
The chart of Calmar ratio for ACL.AX, currently valued at 0.36, compared to the broader market0.002.004.006.000.362.59
The chart of Martin ratio for ACL.AX, currently valued at 1.44, compared to the broader market0.0010.0020.001.4410.80
ACL.AX
^GSPC

The current Australian Clinical Labs Limited Sharpe ratio is 0.64. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Australian Clinical Labs Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
0.64
2.66
ACL.AX (Australian Clinical Labs Limited)
Benchmark (^GSPC)

Dividends

Dividend History

Australian Clinical Labs Limited provided a 3.47% dividend yield over the last twelve months, with an annual payout of A$0.12 per share.


5.00%10.00%15.00%A$0.00A$0.10A$0.20A$0.30A$0.40A$0.50202220232024
Dividends
Dividend Yield
PeriodTTM202420232022
DividendA$0.12A$0.12A$0.14A$0.53

Dividend yield

3.47%3.49%4.84%17.79%

Monthly Dividends

The table displays the monthly dividend distributions for Australian Clinical Labs Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025A$0.00A$0.00
2024A$0.00A$0.00A$0.03A$0.00A$0.00A$0.00A$0.00A$0.00A$0.09A$0.00A$0.00A$0.00A$0.12
2023A$0.00A$0.00A$0.07A$0.00A$0.00A$0.00A$0.00A$0.00A$0.07A$0.00A$0.00A$0.00A$0.14
2022A$0.12A$0.00A$0.00A$0.00A$0.00A$0.41A$0.00A$0.00A$0.00A$0.00A$0.53

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%3.5%
Australian Clinical Labs Limited has a dividend yield of 3.47%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%83.3%
Australian Clinical Labs Limited has a payout ratio of 83.33%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-32.08%
-2.67%
ACL.AX (Australian Clinical Labs Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Australian Clinical Labs Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Australian Clinical Labs Limited was 58.76%, occurring on May 28, 2024. The portfolio has not yet recovered.

The current Australian Clinical Labs Limited drawdown is 32.08%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-58.76%Jan 5, 2022604May 28, 2024
-11.51%Sep 28, 202112Oct 13, 202143Dec 13, 202155
-10.29%Jun 8, 202116Jun 30, 202121Jul 29, 202137
-6.64%Aug 17, 20212Aug 18, 20216Aug 26, 20218
-4.63%May 24, 20217Jun 1, 20212Jun 3, 20219

Volatility

Volatility Chart

The current Australian Clinical Labs Limited volatility is 7.77%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%16.00%AugustSeptemberOctoberNovemberDecember2025
7.77%
3.34%
ACL.AX (Australian Clinical Labs Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Australian Clinical Labs Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Australian Clinical Labs Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab